The global pancreatic cancer market will be valued at around US$ 2,125.57 Million in 2023. The market of Pancreatic Cancer is projected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033.
Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | US$ 1,872.75 Million |
| Expected Market Value (2023) | US$ 2,125.57 Million |
| Projected Forecast Value (2033) | US$ 7,541.09 Million |
| Global Growth Rate (2023 to 2033) | 13.5% CAGR |
| Expected Market Share of the USA Market (2033) | 53% |
| Anticipated Market Value of Europe (2023 to 2033) | 31% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Despite advances in surgical technique, chemotherapy treatments, and the emergence of neoadjuvant chemoradiotherapy, five-year survivorship from this ailment is as low as 2.5% in certain countries. The total number of reported cases of pancreatic cancer in the 7MM nations was around 175,770 in 2021, and this was predicted to increase market growth during the historical period.
The upsurge of an unhealthy lifestyle and poor diet has heightened the number of individuals suffering from pancreatic diseases/conditions. The high incidence of diabetes patients has been mainly ascribed to the rising demand for packaged foods and beverages with elevated amounts of sugar, which also significantly contributes to the growing cases of pancreatic cancer patients. Thus, these factors will drive the market growth during the forecast period with a CAGR of 13.5%.
Owing to the lack of therapeutic procedures for early diagnosis, the pancreatic cancer market is expanding in developed nations
The American Society of Clinical Oncology predicts that 62,210 adults in the USA will be diagnosed with pancreatic cancer in 2022. The high prevalence of pancreatic cancer, which causes germline mutations, is also predicted to boost overall growth.
Besides that, the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to the body's healthy peripheral cells. The industry is being influenced by the increasing prevalence of pancreatic cancer and the requirement for targeted therapy.
NCI-funded research projects to empower the market to grow
The National Cancer Institute has sponsored several research programs dedicated to developing treatments and medications for pancreatic cancer. The Pancreatic Cancer Cohort Consortium, Pancreatic Cancer Cancer Detection Consortium (PCDC), Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC), Pancreatic Cancer Microenvironment Network (PaCMEN), RAS Initiative, Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), and others are instances of financed projects.
These programs each have their mission and targets, and they each seek to find novel solutions to the ailment. The Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), for instance, is an intervention designed to quickly implement principal scientific discoveries into medical settings. The Pancreatic SPORE grants promote novel and diverse methods of prevention and treatment.
Principal Consultant
rising costs of drug development and treatment, along with strict regulatory guidelines to constrain market growth
The elevated cost of drug advancement and treatment may stifle future growth. During the projected timeframe, the market will also face obstacles from stringent government laws and regulations. Inventions and comprehensive authorization methods can assist in overcoming these challenges and propelling the global pancreatic cancer market forward.
In 2021, the North American pancreatic cancer market dominated the global market. This is because pancreatic cancer is more prevalent in North American countries, with the USA having the most cancer victims globally. As a consequence, North America possessed the leading revenue proportion in the pancreatic cancer treatment market in 2021. It is primarily owing to the upgraded healthcare system, widespread utilization of pancreatic treatment procedures, and a huge target citizenry. Furthermore, the increasing prevalence of pancreatic cancer is driving up requirements for treatment options.
The Asia-Pacific pancreatic cancer market is expected to be the most rapidly sprouting in the globe. Asia Pacific, as a result, hand, is projected to expand the fastest during the projected timeline. The existence of well-established clinics and critical care centers, as well as a massive population suffering from pancreatic cancer, would help the industry develop in the Asia Pacific region. Furthermore, with the increasing number of pancreatic cancer cases in Asia Pacific, pancreatic cancer diagnosis and treatment must abide by the same protocol as in Western nations.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The rapid rise of pancreatic cancer patients and, increased investment in healthcare infrastructure propel the market
In North America, the USA of America leads the pancreatic cancer market. Based on the American Cancer Society's National Survey, approximately 3% of cancers in the USA were pancreatic by 2021. Moreover, pancreatic cancers account for 9% of all cancer deaths. The rising number of pancreatic cancer patients is accompanied by higher investment in medical infrastructure.
The simplification of regulatory approval processes has resulted in the safe and prompt approval of clinical drugs and treatments in the USA, contributing to the rising demand for pancreatic cancer treatment options in the country.
Surging tobacco consumption levels will propel the market forward
Germany had the highest number of cases reported of pancreatic cancer in Europe in 2021, with 21,859 cases. Rising tobacco consumption rates and a boost in cigarette smokers are expected to boost the expansion of the pancreatic cancer market.
Rising cancer prevalence, increased alcohol consumption, rising obesity rates, and increasing acceptance of various treatment options available are all forecasting overall growth in this country.
Country-wise Forecast CAGRs for the Pancreatic Cancer Industry
| China | 12% |
|---|---|
| USA | 13.7% |
| Australia | 10% |
| France | 11% |
The hospital's segment is dominant owing to the modern infrastructure
Based on end-user, the Hospital segment is the largest profit segment in the global pancreatic cancer therapeutics market, and this trend is expected to persist in the forecast years. The hospital segment is dominant owing to the quick influx of patients admitted to hospitals due to competent medical practitioners and the accessibility of multiple systems. In addition, hospitals have the decent infrastructure and a wide network, which is cruising market growth. The hospital segment accounted for a 48% share of the market in 2022.
Surgery and radiology segments are expected to lead the industry
Because of the incidence of these methodologies, treatment-type segments such as surgery and radiology are likely to dominate the market throughout the forecast period.
The prominence of targeted drugs and unique biologic therapeutics can also be credited to this segment's supremacy. Furthermore, personalized treatment systems are assisting in the segment's advancement.
Key players in the pancreatic cancer market are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 2,125.57 Million |
| Projected Forecast Value (2033) | US$ 7,541.09 Million |
| Global Growth Rate (2023 to 2033) | 13.5% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
As of 2022, the Pancreatic Cancer market was worth US$ 73.75 Million.
Fact.MR foresees Pancreatic Cancer demand to reach US$ 2125.57 Million in 2023.
From 2023 to 2033, Fact.MR expects Pancreatic Cancer revenue to flourish at a 13.5% CAGR.
In 2033, Pancreatic Cancer market worth is poised to reach US$ 7541.09 Million.
North American regional market is expected to rise 1.4X by 2033.
The USA is expected to possess a 35% market share for Pancreatic Cancer in 2033.
1. Executive Summary | Pancreatic Cancer Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Chemotherapy
5.3.2. Immunotherapy
5.3.3. Hormone Therapy
5.3.4. Surgery
5.3.5. Radiation Therapy
5.3.6. Targeted Drug Therapy
5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Cancer Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cancer Type, 2023 to 2033
6.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Cancer Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Diagnostic Laboratories
7.3.4. Research Institutes
7.3.5. Research Laboratories
7.3.6. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Treatment Type
9.2.3. By Cancer Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By Cancer Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment Type
10.2.3. By Cancer Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Cancer Type
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Treatment Type
11.2.3. By Cancer Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Cancer Type
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Treatment Type
12.2.3. By Cancer Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Cancer Type
12.3.4. By End User
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Treatment Type
13.2.3. By Cancer Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Cancer Type
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. United States of America
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Treatment Type
14.1.2.2. By Cancer Type
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Treatment Type
14.2.2.2. By Cancer Type
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Treatment Type
14.3.2.2. By Cancer Type
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Treatment Type
14.4.2.2. By Cancer Type
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Treatment Type
14.5.2.2. By Cancer Type
14.5.2.3. By End User
14.6.United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Treatment Type
14.6.2.2. By Cancer Type
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Treatment Type
14.7.2.2. By Cancer Type
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Treatment Type
14.8.2.2. By Cancer Type
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Treatment Type
14.9.2.2. By Cancer Type
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Treatment Type
14.10.2.2. By Cancer Type
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Treatment Type
14.11.2.2. By Cancer Type
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Treatment Type
14.12.2.2. By Cancer Type
14.12.2.3. By End User
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Treatment Type
14.13.2.2. By Cancer Type
14.13.2.3. By End User
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Treatment Type
14.14.2.2. By Cancer Type
14.14.2.3. By End User
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Treatment Type
14.15.2.2. By Cancer Type
14.15.2.3. By End User
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Treatment Type
14.16.2.2. By Cancer Type
14.16.2.3. By End User
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Treatment Type
14.17.2.2. By Cancer Type
14.17.2.3. By End User
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Treatment Type
14.18.2.2. By Cancer Type
14.18.2.3. By End User
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Treatment Type
14.19.2.2. By Cancer Type
14.19.2.3. By End User
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Treatment Type
14.20.2.2. By Cancer Type
14.20.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Treatment Type
15.3.3. By Cancer Type
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Pfizer Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Novartis AG
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Eli Lilly and Company
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Bristol Myers Squibb Company
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Zydus Cadila
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. AstraZeneca PLC
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Myriad Genetics Inc.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. F Hoffmann-La Roche Ltd.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. PharmaCyte Biotech Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Teva Pharmaceutical Industries Ltd.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Pancreatic Cancer Market
